216 results on '"Console, Giuseppe"'
Search Results
2. Impact of second-degree related donor on the outcomes of T cell-replete haploidentical transplantation with post-transplant cyclophosphamide
3. Correction to: Effectiveness of biosimilar pegfilgrastim in patients with multiple myeloma after high‑dose melphalan and autologous stem cell transplantation
4. The power of telemedicine to improve CAR-T cell therapy programs: lessons learned from COVID-19 pandemic
5. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience
6. Long-term survival in a fraction of patients with metastatic breast cancer who received consolidation therapy with high-dose chemotherapy and autologous stem cell transplant between 2000 and 2015: an EBMT registry-based study
7. Granisetron transdermal system and dexamethasone for the prevention of nausea and vomiting in multiple myeloma patients receiving chemo-mobilization: An observational real-world study of effectiveness and safety
8. Impact of donor age and kinship on clinical outcomes after T-cell–replete haploidentical transplantation with PT-Cy
9. Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs
10. A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant
11. Challenge to Predict Mobilized Peripheral Blood Stem Cells on the Fourth Day of Granulocyte Colony-Stimulating Factor Treatment in Healthy Donors: Predictive Value of Basal CD34+ Cell and Platelet Counts
12. Autologous Stem Cell Transplantation in Patients With Multiple Myeloma: An Activity-based Costing Analysis, Comparing a Total Inpatient Model Versus an Early Discharge Model
13. High-Dose Melphalan Plus Thiotepa as Conditioning Regimen before Second Autologous Stem Cell Transplantation for “De Novo” Multiple Myeloma Patients: A Phase II Study
14. Mobilization of Hematopoietic Stem Cells with Lenograstim in Healthy Donors: Efficacy and Safety Analysis According to Donor Age
15. Tolerability and Efficacy of Busulfan and Fludarabine As Allogeneic Pretransplant Conditioning Therapy in Acute Myeloid Leukemia: Comparison With Busulfan and Cyclophosphamide Regimen
16. Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study
17. Long-Term Results in Multiple Myeloma After High-Dose Melphalan and Autologous Transplantation According to Response Categories in the Era of Old Drugs
18. Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological Malignancies
19. Identifying and Managing CAR T-Cell–Mediated Toxicities: on behalf of an Italian CAR-T Multidisciplinary Team
20. Netupitant/palonosetron without dexamethasone for preventing nausea and vomiting in patients with multiple myeloma receiving high-dose melphalan for autologous stem cell transplantation: a single-center experience
21. The Burden in Caregivers of Multiple Myeloma Patients Undergoing Outpatient Autologous Stem-Cell Transplantation Compared to Inpatient Transplantation
22. Administration of recombinant human erythropoietin alpha before autologous stem cell transplantation reduces transfusion requirement in multiple myeloma patients
23. Different γ/δ T clones sustain GVM and GVH effects in multiple myeloma patients after non-myeloablative transplantation
24. Internal Iliac Artery Perforation following Bone Marrow Aspiration in a Patient with No Previously Identified Risk Factors: A Case Report and Review of the Literature
25. Long-Term Remission Achieved by Ponatinib and Donor Lymphocytes Infusion in a Ph+ Acute Lymphoblastic Leukemia Patient in Molecular Relapse After Allogenic Stem Cell Transplant and Dasatinib: A Case Report
26. A comparative effectiveness study of lipegfilgrastim in multiple myeloma patients after high dose melphalan and autologous stem cell transplant
27. Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma
28. WERNICKEʼS ENCEPHALOPATHY AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
29. UTILITY OF THE CLINICAL PRACTICE OF ADMNISTERING THROMBOPHILIC SCREENING AND ANTITHROMBOTIC PROPHYLAXIS WITH LOW-MOLECULAR-WEIGHT HEPARIN TO HEALTHY DONORS TREATED WITH G-CSF FOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS
30. Low tolerance and high toxicity of thalidomide as maintenance therapy after double autologous stem cell transplant in multiple myeloma patients
31. High-Dose Therapy and Autologous Peripheral Blood Stem Cells Transplantation Followed by a Very Low Reduced Intensity Regimen With Fludarabine + Cyclophosphamide and Allograft Improve Complete Remission Rate in De Novo Multiple Myeloma Patients
32. Pegfilgrastim compared with filgrastim after high-dose melphalan and autologous hematopoietic peripheral blood stem cell transplantation in multiple myeloma patients
33. Predictive Factors That Affect the Mobilization of CD34+ Cells in Healthy Donors Treated With Recombinant Granulocyte Colony-Stimulating Factor (G-CSF)
34. Harvesting Peripheral Blood Progenitor Cells From Healthy Donors: Retrospective Comparison of Filgrastim and Lenograstim
35. AUTOLOGOUS STEM CELL TRANSPLANTATION (AutoSCT) FOLLOWED BY A NON-MYELOABLATIVE CONDITIONING AND ALLOGENEIC STEM CELL TRANSPLANTATION (AlloSCT) AS CONSOLIDATION THERAPY FOR MULTIPLE MYELOMA (MM)
36. A STUDY OF FEASIBILITY AND TOXICITY OF MULTIPLE CYCLES OF HIGH-DOSE MELPHALAN (HDM) FOLLOWED BY AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (APBSCT) IN ELDERLY PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM)
37. MOBILIZATION OF CD34+ CELLS BY GLYCOSYLATED AND NON-GLYCOSYLATED G-CSF IN HEALTHY DONORS: A COMPARATIVE STUDY
38. A TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOETIN BEFORE AUTOLOGOUS STEM CELL TRANSPLANTATION SIGNIFICANTLY REDUCES TRANSFUSION REQUIREMENT IN MULTIPLE MYELOMA PATIENTS
39. A Comparative Assessment of Quality of Life in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Through an Outpatient and Inpatient Model
40. Identifying and managing CAR T-cell–mediated toxicities: on behalf of an Italian CAR-T multidisciplinary team
41. REPEATED COURSES OF HIGH-DOSE MELPHALAN (HDM) WITH SUPPORT OF PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT) MAY IMPROVE PROGNOSIS IN PATIENTS AFFECTED BY MULTIPLE MYELOMA (MM)
42. INFECTIOUS COMPLICATIONS IN BREAST CANCER (BC) PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) AFTER HIGH DOSE CHEMOTHERAPY (HDC): A SINGLE CENTER RETROSPECTIVE ANALYSIS TOWARDS OUTPATIENT STRATEGY
43. AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) AFTER HIGH DOSE CHEMOTHERAPY (HDC) INFLUENCES THE OUTCOME OF PROGRESSION FREE (PFS) AND OVERALL SURVIVAL (OS) IN METASTATIC BREAST CANCER (MBC) PATIENTS CLASSIFIED ACCORDING TO A RISK GROUP SCORE
44. Quality of life outcomes in multiple myeloma patients: a summary of recent clinical trials
45. The use of ibrutinib before and after allogeneic stem cell transplantation
46. In vitro drug-induced cytotoxicity predicts clinical response to fludarabine in B-cell chronic lymphocytic leukaemia
47. Can we improve the conditioning regimen before autologous stem cell transplantation in multiple myeloma?
48. Single Step Multiple Genotyping by MALDI-TOF Mass Spectrometry, for Evaluation of Minor Histocompatibility Antigens in Patients Submitted to Allogeneic Stem Cell Transplantation from HLA-Matched Related and Unrelated Donor
49. Basal CD34+ Cell Count Predicts Peripheral Blood Hematopoietic Progenitor Cells Mobilization in Healthy Donors after Administration of G-CSF
50. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.